Effect of sirolimus on erythropoiesis of K562 cell line and patients with pure red cell aplasia in vitro.
10.3760/cma.j.issn.0253-2727.2018.04.011
- VernacularTitle:西罗莫司对K562细胞系及获得性纯红细胞再生障碍原代细胞红系分化作用的研究
- Author:
Chen YANG
1
;
Fang Fei CHEN
;
Zhang Biao LONG
;
Ya Li DU
;
Hong Min LI
;
Miao CHEN
;
Bing HAN
Author Information
1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Erythroid-burst forming unit;
K562 cells;
Pure red cell aplasia;
Serum;
Sirolimus
- MeSH:
Erythroid Precursor Cells;
Erythropoiesis;
Humans;
K562 Cells;
Red-Cell Aplasia, Pure;
Sirolimus
- From:
Chinese Journal of Hematology
2018;39(4):310-313
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To understand the effect of sirolimus on the erythropoiesis of K562 cell line and bone marrow cells from pure red cell aplasia (PRCA) patients and normal controls. Methods: Different concentrations (10, 100, 1 000 nmol/L) of sirolimus were added to the K562 cell line or bone marrow cells from PRCA patients or normal controls and cultured 14 days for BFU-E formation. Meanwhile, sirolimus was also added to the serum treated PRCA bone marrow cells to cultivate for the same priod of time. Results: Neither K562 cells, bone marrow cells from PRCA patients or normal controls showed any difference when sirolimus was added to the culture system for BFU-E. However, BFU-E formation decreased after serum was added in PRCA patients (76.40±22.48 vs 136.33±12.58, t=-4.329, P=0.001) and this suppression of BFU-E was partly corrected by 1 000 nmol/L sirolimus treatment (97.14±15.83 vs 76.40±22.48, P=0.038). Conclusions: Sirolimus may modulate the suppression of erythropoiesis by serum instead of directly stimulate the growth of red blood cells in PRCA patients.
